image 2 image 4
Skip Navigation Links
 Home 
 Congress Structure 
 Important Dates 
 Venue 
 Registration 
 Pre Registered 
 Abstracts 
 Scientific Program 
 Exhibition 
 Contact Us 
 Personal page 
 Photo and Film Festival 
       XXVII Annual Congress of the Iranian Society of Ophthalmology        بـیــست و هفتمین کنــگــره سـالیـانه انـجـمـن چـشـم پـزشـکی ایـــران
مقاله Abstract


Title: Treatment of Epidemic Keratoconjunctivitis with a Combination of Povidone-Iodine drops: A Controlled Randomized Study
Author(s): Mohammad Hossein Validad, Gholamreza Seyedpiran, Seyed Sajad Ahmadi, Omid Bagherzadeh, Keyvan Behkam Rad, Hamideh Sabbaghi
Presentation Type: Oral
Subject: Cornea and Anterior Segment
Others:
Presenting Author:
Name: Hamideh Sabbaghi
Affiliation :(optional) Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
E mail: sabbaghi_h@yahoo.com
Phone: 02122808857
Mobile: 09120285930
Purpose:

To investigate the therapeutic effect of topical povidone-iodine (PVP-I) in patients suffering from EKC under the controlled study condition.

Methods:

In this double masked randomized clinical trial, a total of 60 patients with EKC and a mean age of 27.8±12.4 years old were examined at Alzahra Eye Hospital, Zahedan, Iran. The study population were classified into the three groups in which 20 patients were investigated. Cases in group I were received PVP-I drop 0.4%, betamethasone drop 0.1 %, and artificial tear drop and cases in group II were installed PVP-I drop 0.2%, betamethasone drop 0.1%, and artificial tear drop. In addition, controls in group III were received betamethasone drop 0.1%, artificial tear drop, and chloramphenicol drop. Conjunctival injection and discharge, chemosis, periorbital edema, hemorrhage and sub-epithelial opacity were recorded. Comprehensive examinations were performed at baseline and at 4, 7 and 10 days after the treatment.

Results:

Statistical analysis reveals that infectious discharges in groups with a history of PVP-I usage were less and they were being recovered more and faster compared to the control group (P=0.001, P=0.004). In addition, there was a higher amount of sub-epithelial opacity in the groups using PVP-I (group I, 30%, group II, 20% vs. group III, 10%). There was not any statistically significant difference regarding other recorded outcomes among the three study groups.

Conclusion:

Based on our findings, PVP-I could be effective in the fast treatment of EKC. The prescription of PVP-I seems to be challenging due to the induced sub-epithelial opacity after the treatment.

Attachment:





Skip Navigation Links
        صفحه اصلی
        ساختار کنگره
        تاریخ های مهم
        مکان برگزاری
        ثبت نام
        ثبت نام شدگان
        اطلاعات هتل - رزرو
        مقالات
        برنامه کنگره
        جشنواره فیلم و عکس
        نمایشگاه
        تماس با ما
        صفحه شخصی
        جستجوی سخنران
        آرشیو کنگره سالهای گذشته
        شب کنگره چشم پزشکی
 
ورود شرکت کنندگان
نام کاربری :
کلمه عبور :
  کلمه عبور خود را فراموش کرده ام.
Total Visits
Find us on Social Media
Congress Count Down
Today Label
Last Month Label
Total Visitors Label